Moreover,
Komboglyze: marketing stop anticipate |:
Astrazeneca announced the stopping of marketing of its oral antidiabetic Komboglyze (saxagliptin/chlorhydrate of Metformin). Moreover, from January 30, 2026.
The Komboglyze 2.5 mg/1. Nevertheless, 000 mg specialty, film -coated tablet (saxagliptin/chlorhydrate of metformin) will no longer be marketed from January 30, 2026 “Due to commercial considerations”, announced the Astrazeneca laboratory in a letter addressed to healthcare professionals on July 15. Effectiveness, tolerance or the manufacturing quality of the drug is not called into question, would like to reassure the laboratory.
Patients concerned should be informed and oriented towards their doctor quickly to find an alternative therapy.
Comboglyze is indicated in adult patients with type 2 diabetes insufficiently controlled by metformin alone. in combination with other antidiabetics (1 tablet twice per day). SAXAGLIPTINE alone (NAnglyza. Generics) is available in the form of film -coated tablets dosed at 5 mg to be komboglyze: marketing stop anticipate | administered 1 time a day (except particular populations).
komboglyze: marketing stop anticipate | — Komboglyze: marketing stop anticipate |: Astrazeneca announced the stopping of marketing of its oral antidiabetic Komboglyze (saxagliptin/chlorhydrate of Metformin). from January 30, 2026. The Komboglyze 2.5 mg/1,000 mg specialty, film -coated tablet (saxagliptin/chlorhydrate of .
Further reading: For decades, the pain in the installation of the IUD has been ignored, it is changing – The Festival of the Horse and the Toro is fast approaching – Thyroid: Stop for marketing a treatment of Sanofi in France – 07/17/2025 at 15:36 – These unknown signs not to ignore aufeminin.com – Millions of French people take these drugs, they can cause skin reactions to the sun.
